William Blair Issues Negative Estimate for LH Earnings

Laboratory Co. of America Holdings (NYSE:LH - Free Report) - Stock analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Laboratory Co. of America in a research report issued on Monday, February 10th. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of $3.57 for the quarter, down from their prior estimate of $3.69. The consensus estimate for Laboratory Co. of America's current full-year earnings is $15.96 per share. William Blair also issued estimates for Laboratory Co. of America's Q3 2025 earnings at $4.19 EPS, Q4 2025 earnings at $4.23 EPS, FY2025 earnings at $16.00 EPS, Q1 2026 earnings at $4.01 EPS, Q2 2026 earnings at $4.33 EPS, Q3 2026 earnings at $4.44 EPS, Q4 2026 earnings at $4.52 EPS and FY2026 earnings at $17.30 EPS.

A number of other equities research analysts also recently commented on the company. Bank of America raised their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the company a "buy" rating in a report on Friday, December 13th. Evercore ISI raised Laboratory Co. of America from an "in-line" rating to an "outperform" rating and lifted their price target for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. Jefferies Financial Group lifted their price target on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. StockNews.com raised Laboratory Co. of America from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Robert W. Baird lifted their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $265.31.

Laboratory Co. of America Price Performance

Laboratory Co. of America stock traded up $1.87 during midday trading on Wednesday, reaching $246.74. The company's stock had a trading volume of 565,887 shares, compared to its average volume of 603,727. Laboratory Co. of America has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The stock's 50 day simple moving average is $237.42 and its 200 day simple moving average is $230.91. The firm has a market capitalization of $20.64 billion, a PE ratio of 27.98, a P/E/G ratio of 1.84 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%.

Institutional Trading of Laboratory Co. of America

A number of institutional investors have recently modified their holdings of the company. Private Trust Co. NA grew its holdings in shares of Laboratory Co. of America by 3.2% during the 3rd quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company's stock worth $300,000 after purchasing an additional 41 shares during the period. Empowered Funds LLC grew its holdings in shares of Laboratory Co. of America by 0.5% during the 4th quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company's stock worth $1,840,000 after purchasing an additional 43 shares during the period. SP Asset Management LLC grew its holdings in shares of Laboratory Co. of America by 0.3% during the 4th quarter. SP Asset Management LLC now owns 15,186 shares of the medical research company's stock worth $3,483,000 after purchasing an additional 43 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in shares of Laboratory Co. of America by 0.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,780 shares of the medical research company's stock worth $2,931,000 after purchasing an additional 45 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its position in Laboratory Co. of America by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,194 shares of the medical research company's stock worth $1,650,000 after acquiring an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company's stock.

Insider Buying and Selling at Laboratory Co. of America

In other news, CMO Amy B. Summy sold 3,672 shares of the business's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $238.91, for a total transaction of $877,277.52. Following the completion of the sale, the chief marketing officer now owns 4,318 shares in the company, valued at approximately $1,031,613.38. The trade was a 45.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kerrii B. Anderson sold 1,000 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now owns 12,722 shares of the company's stock, valued at $2,989,670. The trade was a 7.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,504 shares of company stock worth $5,905,692 in the last 90 days. 0.85% of the stock is owned by company insiders.

Laboratory Co. of America Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America's dividend payout ratio (DPR) is 32.65%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.